ACST - acastipharma.com Debt to Book Capitalization Ratio

Acasti Pharma (ACST) develops unique therapies for orphan nervous system pathologies, backed by FDA exclusivity protections. The debt-to-equity ratio demonstrates financial stability, with the metric reaching 0.00. Physicians value Acasti Pharma for its pursuit of solutions to complex cardio-metabolic issues, while the company achieves cost optimization by outsourcing trials to external CRO networks.

Debt to Book Capital: Acasti Pharma Inc. (ACST) for 07/04/2022 - 10/28/2024

Metric breakdowns and analytics for acastipharma.com (ACST)

- price and consensus price forecast:

Stock Price Acasti Pharma Inc.|ACST - Analyst Consensus Forecast

- market capitalization data:

Market Value ACST|ACST - Value Adjusted for Debt and Cash

- book capitalization data:

Accounting Value per Share Acasti Pharma|ACST - Total Net Assets|Market Capitalization to Book Value Ratio acastipharma.com|ACST - Company Total Assets

- debt and liquidity data:

Total Debt to Capital Acasti Pharma|ACST - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Acasti Pharma Inc.|ACST - Company Aggregate Debts|Debt to Book Capitalization Ratio ACST

Summary company analytics:Acasti

Manufactured products of acastipharma.com

Investors use this indicator to assess long-term financial stability and bankruptcy risks. The metric is calculated as the ratio of total debt to total equity, determining the business's degree of reliance on borrowings. The current value of 0.00 on the leverage chart—debt to book capitalization—reflects the current balance of liabilities. A decrease in this ratio confirms the solvency of Acasti Pharma (ACST). This is critically important for financing the development of innovative mucosal drug delivery systems.

Competitors of Acasti Pharma (ACST)